全文获取类型
收费全文 | 206135篇 |
免费 | 18023篇 |
国内免费 | 6165篇 |
专业分类
耳鼻咽喉 | 1395篇 |
儿科学 | 4891篇 |
妇产科学 | 2073篇 |
基础医学 | 30662篇 |
口腔科学 | 3813篇 |
临床医学 | 20644篇 |
内科学 | 32095篇 |
皮肤病学 | 2700篇 |
神经病学 | 10727篇 |
特种医学 | 4081篇 |
外国民族医学 | 28篇 |
外科学 | 16898篇 |
综合类 | 32170篇 |
一般理论 | 27篇 |
预防医学 | 13896篇 |
眼科学 | 4731篇 |
药学 | 21799篇 |
42篇 | |
中国医学 | 11198篇 |
肿瘤学 | 16453篇 |
出版年
2024年 | 161篇 |
2023年 | 3062篇 |
2022年 | 4146篇 |
2021年 | 7230篇 |
2020年 | 7334篇 |
2019年 | 7400篇 |
2018年 | 6888篇 |
2017年 | 7250篇 |
2016年 | 7159篇 |
2015年 | 7153篇 |
2014年 | 11745篇 |
2013年 | 12761篇 |
2012年 | 11185篇 |
2011年 | 12652篇 |
2010年 | 10688篇 |
2009年 | 10228篇 |
2008年 | 10161篇 |
2007年 | 10922篇 |
2006年 | 9863篇 |
2005年 | 9636篇 |
2004年 | 8242篇 |
2003年 | 7173篇 |
2002年 | 5422篇 |
2001年 | 5295篇 |
2000年 | 4376篇 |
1999年 | 3945篇 |
1998年 | 2698篇 |
1997年 | 2380篇 |
1996年 | 2471篇 |
1995年 | 2451篇 |
1994年 | 2157篇 |
1993年 | 1977篇 |
1992年 | 1706篇 |
1991年 | 1480篇 |
1990年 | 1240篇 |
1989年 | 1140篇 |
1988年 | 1057篇 |
1987年 | 843篇 |
1986年 | 639篇 |
1985年 | 829篇 |
1984年 | 826篇 |
1983年 | 560篇 |
1982年 | 664篇 |
1981年 | 562篇 |
1980年 | 475篇 |
1979年 | 428篇 |
1978年 | 329篇 |
1977年 | 272篇 |
1976年 | 296篇 |
1975年 | 188篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
3.
《The Journal for Nurse Practitioners》2022,18(5):580-582
Obstructive sleep apnea (OSA) is a sleep disorder common among patients with type 2 diabetes (T2D). The aim of this quality improvement project was to increase identification and referral for sleep study for individuals with T2D at moderate to high risk for OSA. Pre- and post-intervention patient samples were analyzed to compare the number of referrals for sleep study. Results demonstrated that none of the patients pre-intervention were referred for sleep study compared with 77% of patients post-intervention. This project demonstrated implementing an evidence-based tool to screen patients with T2D for OSA leads to higher rates of detection and referral. 相似文献
4.
5.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
6.
Since their inception in the 1960s–70s, mesenchymal stem/stromal cells (MSCs) have gained interest because of their differentiation potential, anti-inflammatory effects, and immune-modulating properties. Both cell-based and cell-free MSC treatments show healing capacity in injured tissues. Cell-based treatment comprises MSCs and all secreted products, whereas cell-free treatments include only the secreted products. MSCs are therapeutically administered to many damaged organs owing to their efficacy. Specifically, the eye is a unique organ system to study the effects of MSCs, as treatment is easily applied and measured owing to its external location. The eye holds an immune-privileged status, wherein inflammation and immune responses are innately down-regulated. As excessive inflammation in the cornea often leads to fibrosis and irreversible corneal hazing, many studies have investigated the anti-inflammatory and immune-modulating capacities of MSCs. Decades of research suggest that MSCs modulate the immune response by secreting cytokines, growth factors, and extracellular matrix proteins that inhibit the infiltration of inflammatory cells following injury and promote a healing phenotype via M2 macrophage polarization. MSCs have also shown trans-differentiation potential into cornea-specific cell types during the wound healing process, such as corneal epithelial, stromal, or endothelial cells. This review discusses recent investigations of MSC treatment in the cornea, focusing on therapeutic efficacy, mechanisms, and future directions. 相似文献
7.
8.
9.
10.